Sie sind auf Seite 1von 79

|   



   

O  

 


INT| TI N

       

          


   

   


    N 

   

          

 N            


Taxonomy

    

 !   "

 #   

  T  

 $  

 -  
     %   &'(
Species, disease and their geographical distribution

Old world Form of disease Geographical distribution


Leishmaniasis
  Visceral leishmaniasis#) I    * 
"!#
   # 
 
VL,       
  *  
   VL   - # 
cutaneous * -
leishmaniasis
     cutaneous  *    * 
leishmaniasis   I   

  cutaneous I    
leishmaniasis * *   
    cutaneous    # 
leishmaniasis  
      
rew world Leishmaniasis Form of disease Geographical distribution

 
   complex
   ãucosal leishmaniasis( ( - *  +" 
 
 ãucosal leishmaniasis ! 
   Cutaneous leishmaniasis $
   Cutaneous leishmaniasis %( !  ,  * 

   complex
 
  Cutaneous leishmaniasis  *   - 
        
   Cutaneous leishmaniasis,    " 
      
 
 Cutaneous leishmaniasis,  * "  
      

  *  àisceral leishmaniasis


 *  
I-T |.
              
%
(       èing Ashurbanipal   
7th century BC             
  - 1500 to 2500 BC.

       Aàicenna  10th century AD  


        Balkh sore/

 I1756, Alexander Russell  -  T     


     clinical descriptions     /

 @hysicians in the Indian subcontinent     èala-azar


% á           á
 á meaning black and
meaning feàer    (/

 *              


 !   )I      
          */
 0
 15th and 16th century  - the Inca period  -  
   1àalley sickness11Andean sickness11white
leprosy1     
/

 ,             /I 


   Surgeon major Cunningham  +   I  
   1885            /

 @eter Boroàsky|      T 


        oriental sore 
-   ,  1898         
           2  
       !"/
istory contd͙.
I 1901, Leishman identified               
          1dum-dum feàer1 %       
(       trypanosomes, found for the first time in
India.

*       Captain Charles Donoàan (1863ʹ1951)    


         
 )       
    ãadras, India.

+   Ronald Ross       Leishman-Donoàan bodies   


intracellular stages              .

T         )"            


        Charles Bentley's discoàery of  
 in patients with kala-azar.

T      3   *        -     


-  , ,            Leonard Goodwin   
  pentostam        /
   
 T          -               
 -                    
         /

 *      4    "          


                 %- 
        (    %       
  (/

       /5& "                


             /

 T                "      


       6"  7/ *              
"        /

 T       "         


    
   
      4           
   %|8
!(        
-         /

 ãicrosatellite DrA   the latest    4      


      -   /N*  |N*
 4                
      /

  N*     !|     


               /
  

   ) 

 I    /            

      /  %    (   


                
     /

 I   "             9 


9       /

 T                


:@  @  @  @
 ) the Old world 

      and @  rew world/

 T            !      


       
@hlebotomus Lutzomiya
Different forms of the parasite

 *   
         /
 8               
 
 -    &);<    
 * 
 
 -     $  ,  

*    


   
       /T 
 
/    
   %$   5'''-(/
@romastigote
 I             % (    
 

          
 5=)&= <     5/=);/= <   
 -          
 T                    
 ,                   
      

@romastigote  $ 


  
      
      
N  
* )  
 
   
T    
 
*  kinetoplast  
parabasal body 
3  
blepharoplast %  
       (
-    /
T     
-    
     
     
-

I8.

Types of presentation
 Visceral leishmaniasis %
( á         
              5''>/I 
   "          
     /

 ãucocutaneous leishmaniasis %


(      
  -            
      /

 Cutaneous leishmaniasis %
(      ?
&''   ?  -    
             
    /

 Diffuse cutaneous leishmaniasis %


(     
     /T            
    =')@=>  /
@athogenesis of VL
 -                      
            -        /

 T    actiàate complement by alternate pathway     
       C3b or C3bi.

 T                        


      %A;   glycoprotein and lipophosphoglycan( / T 
                      
         ;  ;    /

 !                   
           phagolysosomes      /
 *     4               
                      /

 I                   


                       
 /

 !         |             
 -                        

      
Leishmania àirus

 I   |N* 

 !       


  

 !               
             /

 T            


               
ost immune response


                  
  -              
  2    /

 *  -  "        


             
   /

 T      -    T)  5%T5(


         &       
5&             /

 *   -            


  -        
     
     T)  &%T&(    /
Leishmaniasis and The Immune System

 I                 
            /

 ,                   /


!               
      /

                  /+  


                      
    /

          "      
          /
Leishmaniasis and The Immune System

 *                  
   /8 -       -   
         /T   
  -   -    /


                 
/

 I   -          
       " /T        
  /T "          
           
  /

 * "       %


!$(   
      " /
Recent studies
Cellular and umoral Immunity in Leishmaniasis

 +  
           
-                 
   /

 T       -  /8 -    


                +) /
 T                 
   
  /

 T     -  |  


  2 
-    B'2/

 I  -             



         /T |  
  
          T /
Recent studies
 *   -        
             
 T5CT&         
               /

 8 -  =@C+
A      
/ 3   
  +C   /

              =@C+


A
       I  $ I
)&
  I
)DI
)5'/

       +*


+C     
I  $ I
)&    I
)DI
)5'/
%
  5EE5(
Recent studies
 I         cytokines     
         /

 I   +*


+C       anti-IL-4     
  
        /T   inhibiting IL-4    
   /

 |  =@C+
A         )I  $     
  
      /

 T   Interferon Gamma        


  /T   
   IL-2 and Interferon Gamma         
       /

   IL-4 and IL-10          
-   /

 8  -             T5CT&


  /%|  5EE=(
Signs and symptoms
                           
                    
       /

 T                      


   /

 T  I            /

 !    )      


)         I$      
       /

 T           


Signs and symptoms

 !          )"     )


  

 * -                


     TN8  I    /

            %      ;)A


  (

 !              


    /

              )    


      % #)" I (
 IV Co-infection
 
CI )    is emerging   -         
     /

 
CI )                    )
         &=>  @'>   
      
I    5/=> E>  *I-        4   
    
/

 Intraàenous drug users                 /

 I             


CI )       
                       
        /

 T            


 *I-      
    the spread of the AIDS pandemic      
    the simultaneous spread of VL from rural to suburban areas/

 T                  


          /
 IV Co-infection

 *              



 "       /

       immunosuppressed % //


  I         
     )  
   ( 4         
       /

 *I-
          /

    


4       *I-%  
           (
      - I)     /

    I  


/*I-    
  
5'')5'''     /
 IV Co-infection

 T                   


    
     I      
-               4  /

 
      3        )   
 /
                 
      
CI  /


                   
                   /

 T             )   /

 +       -  


         !|
   4   A= %=&>(  5&=            
5EEB   =& %;D>(  5=D            &''')
'5/
 IV Co-infection
 Specific @roblems
 
CI)                
  /The usual clinical features (       
        (are not always present/

 T                


            
     /

 The serological diagnosis is falsely negatiàe in 42.6% of co-infected patients/


I)              
           /
 Consequently, there is a need to use two or more serological tests and antigens
freshly prepared         /

 *      "   4 %     
   ( parasitological diagnosis can be difficult and has to be
repeated to orient the treatment.

 Bone marrow aspirate (BãA) remains the safest and most sensitiàe technique,
        /, +* 
     
       
  /
 IV Co-infection
 T  )                /
   patients treatment failure, relapses due to drug resistance -    
 /

 In south-western Europe, follow-up studies using pentaàalent antimonials, the same first-line drug used
to treat classic leishmaniasis       B;> /  52% of patients relapse
within a period of one month to three years,           /

 T                  +      +   


  /T          )      
   -  -   /
Epidemiological Changes :
 
CI)                  
"  
/Co-infected patients harbour a high number of   in their blood so there is also a
risk of them becoming reseràoirs of the disease %         ( 
anthroponotic foci in Bangladesh, India, repal and East Africa.  4         
    /

 Experimentally, sandflies can be infected through a blood meal containing a àery small quantity of blood
from co-infected patients. The quantity may be less than the content of a needle/*@5/5>)   
   )         
  
          /
!#

 I )       9       


     )" /

    5'>  I F;> * /

                  


     /

 $    4   /

 II  !#


     & 
    &'/
!#

Epidemiology

     BB %5A    @&   
  ( =  * * - *  N *   
/

 *        A'''''   /

 *   5&        ;='        
  -/&=> 


 India: #)"         + , + 


!  /-        T !  * 
 $3 /
 * )"      B=  5'''' )  &''D 
DA  5'''' )  &''@/

 T        )" I      
             
     /

 II #)"              


      |3 /
Leishmania tropica complex

 I  
/ 
/ 3 
/    9      
      


/       %   (    *  
       +       /

 T               /

 abitat 
/             % *    
           (       
  /
 T                 
 ãorphology    
/
 Life cycle    
/ -               
       /
 @athogenesis                  
                   
           /
 ! )              9      
          %    ( /
 
Types of Cutaneous leishmaniasis
 T  

â Diffuse cutaneous leishmaniasis 9       poor immune


response               
 F -     &'  /

 Leishmania skin test is negatiàe .

â Leishmaniasis recidiàans           


               
  /

       /

 Skin test strongly positiàe    exaggerated delayed hypersensitiàity


  /

 T          &' /


rew world cutaneous leishmaniasis
   
   comple x%    
 
   
    complex%  
    


  T        /

 8              /


    /

 *              

    


/


   
/  -        |
            /
@athogenesis
 !            - 

        -     
 

           


/"   
     /    --  
   -  
                  
  
 T                
             
Different cutaneous manifestations

 L.braziliensis complex 
 Espundia          
              - 
 @ian bois
/   % 3(     
        
 °ta 
/           
 -       ;  
 

 L.mexicana complex 
 Chiclero ulcer % (
/ -      
    A  
 Indolent nodular lesion 
/  "   
 Cutaneous single sore type 
/ "     
 

rew world VL (AVL)

  
/   - *  %*
(

          

  
      

 *       %    


/  (  
   

 Life cycle & morphology 


/     
   %     (   
     /

 Clinical disease*
          G=
/
Laboratory Diagnosis
 !      
          
   /

 Specimens

 -            

              
      8          

 -   

    -  

  

 

 * I 

 I   

/  
  :

 T     


/ %
 (     
             
    
 $ ,   

 +9    recent method      


            4 
 -            %     
   (
 +    -  CI   

  ) 


N !    A'> 

 !    
       
  +
Brown-opps ãethod

 Fixation
 5'>+  N 8  
 Section
 ! HA 
 Staining @rocedure
    "       /
 !      Crystal Violet Solution1%, *4   /|   
    /
 in Gram's Iodine     /|       /
       Cellosolàe, until blue color no longer streams away from the section %-  =)5'
 (/

 '         /


 - in Basic Fuchsin Solution, 0.5%, *4     /|       /
 Gallego's Solution     /%     1 - 1 + 8  (/
 |              -  % (/
 -     T"  - /I    -  (/
        -4      /
 I      5'   /-      I      /
   !  
*    
    /-  
 )%
(  
   -        /   - 

   /-D''
Culture:

 T          

 NNN%N N N  (  %&F  


      (

 -      %I     (%&'> 


  (   NNN

 $ J   9     


    %I     (

 I &&K)&AK5)D /

 *         -  


   
Animal inoculation

 I     chinese and Golden hamster   


  

 I          


Immunodiagnosis
 T                
                
     - /

 -    )          


                
      /

 -      


 ron- specific tests and specific tests

 I       %I*(

          %I!(

 I    %I( /

 T                  


  
ron- specific serological tests

 T           

 *   N 
 *   

 *      J       3        


   &)&' /

   9          -   3  * 
             /

 I           

 *                
               

Specific immunological tests :
Fluorescent antibody test
 The indirect fluorescent antibody (IFA)        
 )          -    /

 T               the àery
early stages         -      /
 T    5&'     55&B   /     
           /

 T          -  &B/DE;BA/A 


 /T     
 
  
    /

 T     %   (         
 3      /T    as direct
fluorescent test.

 T        more useful    



!#
/
I         -  %|!(   
 /T  not require fluorescence microscope      
   /
Direct agglutination test:
 T         %DAT(   highly specific and sensitiàe test/
 I                    
 /
 *T            E5)5''          @&)
5''        /
 T                      "
   / T  " )              *T 
  
     3    *T        5B 
               / *  *T    
                   
               /

 Recently, Schoone           agglutination-screening  


(FAST)         %L; (  anti-      
          filter paper.

 T 8*-T   "             4    / T


8*-T        *T      " )         
                      /
Enzyme linked immunosorbent assay (ELISA):
 
I-*         most sensitiàe            
    / T           field applications     
             /

 * -                   


 %
)
-(                  
 
I-*/ T 
           5''                !!  EE/EE  
   N!  E=/D=    /

 T        gene B homologue (Ld-rGB@)     


I-* 
                      /

 *         |88   


        
     
 I /

 T |88       


5      ;=   
  
                    /

 I  #;E
I-*           
 
      *I- @B/T      
       )          
    
ELISA

 Very recently,     "    


   I      !"# 

    %#5A(  5''      


   /

 I         #;E    EB  


       I  )" !#
/

 I  5''     #;E   


        ! T /

 T        "   


       
  /
Rapid antibody detection method

 I  
           
  )        
  4  /

 T            


  /,   3        
    I+  %-*(   
)#;E   
   -  
 %I (   
)#)
5A  /

 +          


    /
Antigen detection
 *              
        /

 -        -          


              
            /

 |   -   %#*TI(    


        
 J       /

 T   5''            AB)5''


  /
Leishmanin skin test (LST): ãontenegro test

 0.2 ml of leishmania antigen ( containing 10^8 promastigotes of L.donoàani in


1ml of 0.5% phenol saline ) is injected intradermally. Test is read after 48 to 72
hrs .

 @ositiàe ʹ area of erythema & induration of ш5mm in D ,which heals in 14-25 days
.It indicates prior exposure to leishmanial parasites .

 In kala-azar , it becomes positiàe usually only 6-8 wks after cure from the
disease.

                  
         
      
    /

 N)     J    )   


         /


-T            
              
    /
ãolecular methods
 *          N* |N*
        /

        gene amplification


techniques           
    /

 @olymerase chain reaction (@CR): *       


    !|         
      4           
 /

 T      18S-rRrA,   |N* %--


|N*(        4  N*   - %  
 (     )      A;    
   %IT-(  : )   N*  - ) 
       N*
ãolecular methods
 |    )- "   using @CR-ELISA  &D>
         
 á$    

 I                   


           /

 T                


            !|    /
 +               C - 
           !|      /

 T       !|             


 5''>       B')E;/;>      =')A'>      
    -  /

 *       !|      !|        


       !#
/
ãolecular methods
 T chronic CL          I  
@CR has been proàed to be the most important tool   /T 
    !| 
    5''  /

 *      !|  %    


  (  )          )
    /

 T  ) !|  4   4    


             
          /

 T  "   ) !|        


      /

 T    -!|       -    


    *I- /
Summary of the Diagnosis

       amastigotes       diagnostic gold
standard              
       /

                  


E=>==9E@>A'%,     

                   $ 


               
 )   /

 8 " )   %      (     )#;E
                 
     /

 I     )#;E )        %E'95''>(  


                
     I          !#
/

 Testing urine for leishmanial antigen or antibody is a new approach.

 I           


    N*      !|        
  /
Giemsa-stained splenic Serodiagnosis of kala azar by anti-è39 antibody detection
aspirate smear, showing clumped in immunochromatographic strip test. 5 min after
mononuclear cells and numerous application of one drop of fingerprick blood and buffer,
amastigotes . Original right-hand strip shows second pink band (arrow)
ãagnification X500. indicating presence of anti-è39. Left-hand strip shows a
negatiàe result (no second band).
TREATãErT

 T                     5E''


                 / T    - 
-                 /

 @entaàalent antimony coumpounds        %-( 


          
   /T    
 
Disease Dose Duration

Cutaneous leishmaniasis 20 mg Sb/kg/day 20 days
ãucocutaneous leishmaniasis 20 mg Sb/kg/day 28 days
Visceral leishmaniasis 20 mg Sb/kg/day
 28 days

-       longer courses proàe more effectiàe in preàenting relapse


            )   -  / 8      
                          
         ='>)@'>           5'>  
       /

 Side effects include: Cardiotoxicity, reàersible renal insufficience, pancreatitis, anemia, leukopenia,
rash, headache, abdominal pain, nausea, àomiting, arthralgia, myalgia, thrombocytopenia, and
transaminase eleàation.
Treatment
 Amphotericin B   be more effectiàe    
       -      
- -  /

   more recent deàelopments haàe made Amphotericin B less toxic


   /I          
                 /

 *      +        


            4  /

 Side effects include: feàer nausea, àomiting malaise, anemia, phlebitis, hypokalemia,
hypomagnesemia, and nephrotoxity.

 @entamidine isothionate    )      


              /  
         5EB' 5EE'    

    /N       )   
           /

 Side effects include: nausea, àomiting, abdominal pain, and headache/


Treatment

  * 

 T          


          /

 Cytokine therapy   interferon gamma granulocyte


macrophage colony-stimulating factors        
             /

 ãiltefosine*           


 /*    -  -       
  /
 8            - 
              
VACCIrES:

 Currently there are no drugs or àaccines for the preàention of


Leishmaniasis.


         /

 I      T 5  T &   


       )     /


 )            
                /

 ,    3     )     


    /

  
,  )  
             
       )         /

 !  III            - *       



  +$                   
    /

 |         5B>  @B> %-    5EEB: *  5EBA(/   
                   )   

                   
% 2 M* 5EE;(/

 T       I8N)   T)        T 5


  / T   T 5     -  )     
     
  %*3 5EEE(      
      4               

   /

 I                      


       %  5EB@(/

                   / -  


      )     )        
    % )
 5EEE(/
  

 )  
              
                
   /

 T      )        


              /

 +                 


     )   T)   /

 |             


  
            
    3%|  5EEE(/

     


       
           /
 -  !   

*    T)     A;      T 5


  -  D'@     
  
3 +*
+C  %- " 5EEE(/

  
I         -  I
)5&  
    T 5           
     %$ 5EEE(/

 *    


  %
!$(   
                
 !    4 %T 5EEE(/
 T              
    /

 8                


          /

 I          


  :    "    )
             /

 I     )         


               
   /

 N            


           
        - *  
-/
            
        ) N*  
                  
  /

 *              


      -   
     %A;(        " 
               
       T      /

 *       $!I)     


DA!  - *  &%!-*)&(     
   
    -   

 I  "                


                
                
        /
 -  N*                
            /

 *  -            


   
         %
*#(    -     
       /

 I  "   
*#       -   I
)D
    T             T &   /

       +*
+C   "   
*#      
   4       
 /

 T         


*#         
 
   
*#           
    /
 -                    /

 T           %!(    *&


     !D!B      )55
%#!)55(  
|5       +5%*-!+5(
       |88      !'    &
%!|!)&(N;A      )    
    %!!$(/

 I      *T!      )   
  @')   5           
    /
Vaccines
 T        
 )555       
 /

 )555             :  
 
      )    - %T-*(  
  )   
 )5%
-TI5(         %
I8(/
 I             
 )555  
   
  
   /
 T          
 )555       
              
 )555   
                !  III
  /
 *         
 )55'     
                
         /
  !  III   %     (
 )555  
         +" !   !  I 
   I % CC   /(/
Reference centre
 RAJErDRA ãEãORIAL RESEARC IrSTIT°TE OF ãEDICAL SCIErCES
@ATrA - 800007 %   5EB5(
 @hone: 'A5&)&A;5=A=Fax: 'A5&)&A;D;@EEmail :   H  // 
   H  / Website : CC/  // 
 Scope of Actiàities:
 -  ! + -  |3    |   I  
  -  %||I-(       

    #)"IC*I-/T    
 /||I-      I|    )  
  /
 Thrust Areas:
 !|   
 - 
)I)   
    
           

     
 |           
 I ) !#
 
 I       
          
 |  +      T  
C!#
CI
 
*T 
! 
 - |        $  !  
 
 

Refferences

 T F, J! 5' /


      9$ D /
 ! #//  3 )5& /
 T -    9-//! 3);
/
    9/|/*+/*) & /
 I   
Vaccines

 
            
      /

 -             


    
                 
 )     /

 !  -           


    
   /
 I  "            -  5=
  -!5=      
    /

             


 
M5E     
  "   
          I$&   
   I8N)N /